SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sage Therapeutics (SAGE) PT Raised to $70 at Leerink Partners as New Data Corroborates Prior Promising Results
May 14, 2015 11:03 AM EDTLeerink Partners analyst Paul Matteis reiterated an Outperform rating and boosted his price target on Sage Therapeutics (NASDAQ: SAGE) to $70.00 (from $54.00) after final phase I/II SAGE-457 data corroborates prior promising results.
Matteis commented, "This morning SAGE reported final... More
SAGE Therapeutics (SAGE) Misses Q1 EPS by 17c
May 14, 2015 6:33 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($0.66), $0.17 worse than the analyst estimate of ($0.49).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
... More